Search research articles
Contact Us
Filters
Showing results (1-10 of 404) with videos related to
Page
of 41
Sort By:
The Lancet. Oncology
|
September 1, 2023
Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - Author's reply
Binghe Xu
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 13, 2025
Recent advances in systematic therapy of breast cancer: Chinese contribution for international progress
Yan Wang, Binghe Xu
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 11, 2024
Breast cancer: Epidemiology, risk factors and screening
Hangcheng Xu, Binghe Xu
Plos One
|
August 21, 2015
Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study
Wenjie Zhu, Binghe Xu
Cancer
|
July 26, 2020
Current clinical trials on breast cancer in China: A systematic literature review
Ying Fan, Binghe Xu
Frontiers of Medicine
|
November 11, 2020
Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials
Wenjie Zhu, Binghe Xu
Cancer Communications (London, England)
|
September 8, 2022
Breast cancer: an up-to-date review and future perspectives
Ruoxi Hong, Binghe Xu
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 11, 2024
Preface to Special Issue: Cancer epidemiology, risk factors and screening
Binghe Xu, Hangcheng Xu
Plos One
|
August 8, 2014
MicroRNA-21 identified as predictor of cancer outcome: a meta-analysis
Wenjie Zhu, Binghe Xu
Cancer Innovation
|
June 8, 2026
Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)
Fei Ma, Binghe Xu,
Page
of 41
Search research articles
Search
Showing results (1-10 of 404) with videos related to
Sort By:
Page
of 41
The Lancet. Oncology
|
September 1, 2023
Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - Author's reply
Binghe Xu
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 13, 2025
Recent advances in systematic therapy of breast cancer: Chinese contribution for international progress
Yan Wang, Binghe Xu
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 11, 2024
Breast cancer: Epidemiology, risk factors and screening
Hangcheng Xu, Binghe Xu
Plos One
|
August 21, 2015
Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study
Wenjie Zhu, Binghe Xu
Cancer
|
July 26, 2020
Current clinical trials on breast cancer in China: A systematic literature review
Ying Fan, Binghe Xu
Frontiers of Medicine
|
November 11, 2020
Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials
Wenjie Zhu, Binghe Xu
Cancer Communications (London, England)
|
September 8, 2022
Breast cancer: an up-to-date review and future perspectives
Ruoxi Hong, Binghe Xu
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 11, 2024
Preface to Special Issue: Cancer epidemiology, risk factors and screening
Binghe Xu, Hangcheng Xu
Plos One
|
August 8, 2014
MicroRNA-21 identified as predictor of cancer outcome: a meta-analysis
Wenjie Zhu, Binghe Xu
Cancer Innovation
|
June 8, 2026
Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)
Fei Ma, Binghe Xu,
Page
of 41